BioNTech SE(US:BNTX)2023-05-07 16:00Financial Statements Interim Condensed Consolidated Statements of Profit or Loss The company's total revenue and profit for Q1 2023 significantly decreased year-over-year, primarily due to reduced commercial revenues | Metric | Three Months Ended March 31, 2023 (million Euros) | Three Months Ended March 31, 2022 (million Euros) | | :--- | :--- | :--- | | Total Revenue | 1,277.0 | 6,374.6 | | Cost of Sales | (96.0) | (1,294.1) | | Research and Development Expenses | (334.0) | (285.8) | | Selling and Marketing Expenses | (12.2) | (14.3) | | General and Administrative Expenses | (119.4) | (90.8) | | Other Operating Expenses | (118.1) | (71.6) | | Other Operating Income | 57.1 | 134.7 | | Operating Profit | 654.4 | 4,752.7 | | Finance Income | 82.3 | 272.1 | | Finance Expenses | (29.0) | (6.7) | | Profit Before Income Tax | 707.7 | 5,018.1 | | Income Tax | (205.5) | (1,319.3) | | Profit for the Period | 502.2 | 3,698.8 | | Basic Earnings Per Share | 2.07 | 15.13 | | Diluted Earnings Per Share | 2.05 | 14.24 | - 2023年第一季度总收入同比下降80%，本期利润同比下降86%469624 Interim Condensed Consolidated Statements of Comprehensive Income The company's total comprehensive income for Q1 2023 significantly decreased to 501.8 million Euros from 3,702.4 million Euros in Q1 2022 | Metric | Three Months Ended March 31, 2023 (million Euros) | Three Months Ended March 31, 2022 (million Euros) | | :--- | :--- | :--- | | Profit for the Period | 502.2 | 3,698.8 | | Other Comprehensive Income (to be reclassified to profit or loss) | | | | Exchange Differences | (2.1) | 3.7 | | Net Gain on Cash Flow Hedges | 1.7 | — | | Other Comprehensive Income (not to be reclassified to profit or loss) | | | | Remeasurement Loss on Defined Benefit Plans | — | (0.1) | | Total Comprehensive Income for the Period | 501.8 | 3,702.4 | - 2023年第一季度综合收益净额同比下降86.5%471482 Interim Condensed Consolidated Statements of Financial Position As of March 31, 2023, the company's total assets and liabilities decreased, while total equity slightly increased | Metric | As of March 31, 2023 (million Euros) | As of December 31, 2022 (million Euros) | | :--- | :--- | :--- | | Non-current Assets | 1,992.9 | 1,357.1 | | Current Assets | 20,086.1 | 21,922.0 | | Total Assets | 22,079.0 | 23,279.1 | | Total Equity | 20,265.3 | 20,055.6 | | Non-current Liabilities | 262.8 | 272.9 | | Current Liabilities | 1,550.9 | 2,950.6 | | Total Liabilities | 1,813.7 | 3,223.5 | - 截至2023年3月31日，总资产较2022年12月31日下降5.15%，总负债下降43.75%，总权益增长1.05%499 Interim Condensed Consolidated Statements of Changes in Stockholders' Equity As of March 31, 2023, total stockholders' equity increased to 20,265.3 million Euros, driven by profit for the period, partially offset by share repurchases | Metric | As of March 31, 2023 (million Euros) | As of March 31, 2022 (million Euros) | | :--- | :--- | :--- | | Equity at January 1 | 20,055.6 | 11,893.6 | | Profit for the Period | 502.2 | 3,698.8 | | Other Comprehensive Income/(Loss) | (0.4) | 3.6 | | Share Repurchase Program | (282.0) | — | | Share-Based Payments | 10.9 | 12.2 | | Equity at March 31 | 20,265.3 | 15,910.6 | - 2023年第一季度，本期利润为502.2 million Euros，股份回购计划导致282.0 million Euros的减少484 Interim Condensed Consolidated Statements of Cash Flows For Q1 2023, the company reported net cash outflows of 677.4 million Euros from operating activities, 735.4 million Euros from investing activities, and 291.3 million Euros from financing activities, resulting in a net decrease of 1,704.1 million Euros in cash and cash equivalents | Metric | Three Months Ended March 31, 2023 (million Euros) | Three Months Ended March 31, 2022 (million Euros) | | :--- | :--- | :--- | | Net Cash Flows from Operating Activities | (677.4) | 4,050.2 | | Net Cash Flows from Investing Activities | (735.4) | 287.4 | | Net Cash Flows from Financing Activities | (291.3) | 80.3 | | Net Increase/(Decrease) in Cash and Cash Equivalents | (1,704.1) | 4,417.9 | | Cash and Cash Equivalents at Period End | 12,143.9 | 6,164.1 | - 2023年第一季度，经营活动现金流由2022年同期的净流入4,050.2 million Euros转为净流出677.4 million Euros475118 - 投资活动现金流净流出735.4 million Euros，主要用于金融证券投资475665 Notes to Interim Condensed Consolidated Financial Statements Corporate Information BioNTech SE is a global next-generation immunotherapy company headquartered in Mainz, Germany, focused on developing novel medicines for cancer, infectious diseases, and other serious illnesses - BioNTech SE是一家全球性的下一代免疫疗法公司，致力于开发针对癌症、传染病及其他严重疾病的新型药物477 - 公司总部位于德国美因茨，并已建立起涵盖mRNA疫苗和疗法、细胞和基因疗法、靶向抗体和小分子免疫调节剂等多个技术平台477485 Basis of Preparation, Significant Accounting Policies and Further Accounting Topics These interim condensed consolidated financial statements are prepared in accordance with IAS 34 and IFRS, with accounting policies generally consistent with the 2022 annual report, except for income tax accounting, requiring significant management judgments, estimates, and assumptions - 简明合并财务报表按照国际会计准则（IAS）34《中期财务报告》编制，并遵循国际财务报告准则（IFRS）487485 - 会计政策与2022年年度报告中的审计合并财务报表保持一致，但所得税核算除外490 - 管理层在